Erythropoietic protoporphyria (EPP) is a genetic metabolic disorder belonging to the group of cutaneous porphyrias. It is the most common childhood porphyria 1 with a prevalence ranging from 1.5 to 27.7 per million in Europe. 2 The prevalence in Israel is 1.6 per million, according to a recent study. 3 EPP is characterized by a reduction in activity of ferrochelatase (FECH), the last enzyme of the heme biosynthesis pathway which catalyzes the incorporation of iron into protoporphyrin. The resultant accumulation of the heme precursor